A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Participants With Active, Difficult to Treat Rheumatoid Arthritis

Investigation of an Investigational Medication for Rheumatoid Arthritis (RA)

Recruiting
18 years or above
All
Phase 2
120 participants needed
2 Locations

Study Overview

This Phase 2b, multicenter, double-blind, placebo-controlled, randomized withdrawal study is designed to assess the efficacy and safety of IMVT-1402 in adult participants with active, difficult-to-treat, anti-citrullinated protein autoantibody (ACPA) positive rheumatoid arthritis (RA). The primary objective is to evaluate the effects of IMVT-1402 compared to placebo, as measured by the American College of Rheumatology 20% (ACR20) response.

Study Details

The study consists of several periods. During the Screening Period (5 weeks) participants will undergo screening procedures to determine eligibility. In Period 1 (Open-Label Treatment), all eligible participants will receive open-label treatment with IMVT-1402 at a dose of 600 mg subcutaneous (SC) once weekly (QW) for 16 weeks. Participants who meet the ACR20 response criteria at Weeks 14 and 16 will be randomized in a 1:1:1 ratio to receive blinded treatment with either IMVT-1402 600 mg SC QW, IMVT-1402 300 mg SC QW, or placebo SC QW for 12 weeks in Period 2 (Randomized Withdrawal). Eligible participants who complete Period 2 at Week 28 will have the option to receive IMVT-1402 for an additional 48 weeks in Period 3 (Long -Term Extension). A follow-up visit will occur 4 weeks after the last dose of study treatment to monitor safety.

The primary endpoint of the study is the proportion of participants achieving an ACR20 response at the end of Period 2. Secondary objectives include evaluating the safety and tolerability of IMVT-1402, as well as its effects on other efficacy measures. This study aims to provide valuable data on the use of IMVT-1402 in treating adults with active, difficult-to-treat, ACPR-positive RA.

Eligibility Criteria

You may be eligible for this study if you meet the following criteria:

  • Conditions: Rheumatoid Arthritis
  • Age: 18 years or above
  • Gender: All

Inclusion Criteria:

  • Diagnosis of 'definite RA' according to the 2010 ACR/ European Alliance of Associations for Rheumatology (EULAR) Rheumatoid Arthritis Classification Criteria.
  • Greater than or equal to 6/68 TJC and ≥ 6/66 SJC at both Screening and Baseline visits.
  • C-reactive protein ≥ 1.5 × upper limit of normal (ULN) at Screening Visit.
  • DAS28-CRP > 4.1 at the Screening Visit.
  • Elevated immunoglobulin G (IgG) + ACPA at the Screening Visit.
  • Inadequate response to at least 2 classes of biologic/targeted synthetic DMARDs.

Additional inclusion criteria are defined in the protocol.

Exclusion Criteria:

  • Have received rituximab and experienced insufficient efficacy or loss of efficacy
  • History of any chronic inflammatory arthritis with onset prior to age 18 or history of acute inflammatory joint disease of different origin from RA.
  • Active malignancy or history of malignancy within 5 years prior to Screening Visit.
  • Medical history of primary immunodeficiency, T cell or humoral, including common variable immunodeficiency.
  • Used any non-immunosuppressive Fc-based therapeutic protein (e.g., mAb or Fc-fusion protein) within 4 weeks prior to or at Screening Visit.
  • Used any anti-FcRn treatment within 2 months prior to or at Screening Visit or have a documented history of non-response to prior anti-FcRn treatment.

Other, more specific exclusion criteria are defined in the protocol.

Updated on 01 Feb 2025. Study ID: NCT06754462

This study investigates the effects and safety of an investigational medication in adults with active rheumatoid arthritis (RA), which is a condition where the immune system mistakenly attacks the joints. The purpose of this study is to compare the investigational medication with a placebo, a substance that looks like the medication but does not contain any active medicine, to see how well it works in improving RA symptoms.

Participants will first receive the investigational medication weekly for 16 weeks. If their symptoms improve, they will then be randomly assigned to continue with the medication at different doses or switch to a placebo for another 12 weeks. After this period, they may choose to continue receiving the investigational medication for an additional 48 weeks. A follow-up visit will occur 4 weeks after the last dose to ensure safety.

  • Who can participate: Adults diagnosed with rheumatoid arthritis, who have not responded to at least two RA treatments, may be eligible. Participants must meet criteria for joint tenderness, swelling, and specific blood test results.
  • Study details: Participants will receive an investigational medication through weekly injections under the skin. They may also receive a placebo, which resembles the investigational medication but contains no active substances.

Find a study site near you

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language